US Dollar vs Yen

登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。

ホーム
投資
株式
オーストラリア
ASX
Amplia Therapeutics Limited (ATXOA) 銘柄情報

Amplia Therapeutics Limited (ATXOA)

0.04

0.00

( 0.00% )

更新日時： 10:33:59

Amplia Therapeutics Limited (ATXOA) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

0.04

( - )

買値

0.04

売値

0.045

出来高

50,000

0.04 日の範囲 0.041

0.013 52 週間の範囲 0.23

時価総額

前日終値

0.04

始値

0.04

時刻

最終取引時間

10:33:59

財務取引量

-

VWAP

-

平均取引量 (3 か月)

AUD 4,578,522

発行済株式数

513,312,014

配当利回り

PER

-7.31

1 株当たり利益 (EPS)

-0.02

歳入

4.79M

純利益

-7.71M

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreati... Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia. 詳細を表示

セクター

-

業界

-

ウェブサイト

www.ampliatx.com

本社

Melbourne, Australia

設立

2026

Amplia Therapeutics Limited is listed in the sector of the オーストラリア証券取引所 with ticker ATXOA. The last closing price for Amplia Therapeutics was AUD0.04. Over the last year, Amplia Therapeutics shares have traded in a share price range of AUD 0.013 to AUD 0.23.

Amplia Therapeutics currently has 513,312,014 shares in issue. The market capitalisation of Amplia Therapeutics is AUD20.53 million. Amplia Therapeutics has a price to earnings ratio (PE ratio) of -7.31.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.005	14.2857142857	0.035	0.041	0.03	239402	0.03887628	DE
4	-0.02	-33.3333333333	0.06	0.073	0.03	257789	0.05061859	DE
12	0.015	60	0.025	0.135	0.023	511347	0.08740549	DE
26	0	0	0.04	0.135	0.023	336562	0.07799726	DE
52	0.026	185.714285714	0.014	0.23	0.013	591054	0.09721524	DE
156	0.03	300	0.01	0.23	0.009	558510	0.08429532	DE
260	0.03	300	0.01	0.23	0.009	558510	0.08429532	DE

ATXOA - Frequently Asked Questions (FAQ)

What is the current Amplia Therapeutics Limited share price?

The current share price of Amplia Therapeutics Limited is AUD 0.04

How many Amplia Therapeutics Limited shares are in issue?

Amplia Therapeutics Limited has 513,312,014 shares in issue

What is the market cap of Amplia Therapeutics Limited?

The market capitalisation of Amplia Therapeutics Limited is AUD 20.53M

What is the 1 year trading range for Amplia Therapeutics Limited share price?

Amplia Therapeutics Limited has traded in the range of AUD 0.013 to AUD 0.23 during the past year

What is the PE ratio of Amplia Therapeutics Limited?

The price to earnings ratio of Amplia Therapeutics Limited is -7.31

What is the cash to sales ratio of Amplia Therapeutics Limited?

The cash to sales ratio of Amplia Therapeutics Limited is 12.86

What is the registered address of Amplia Therapeutics Limited?

The registered address for Amplia Therapeutics Limited is 90 William Street, Melbourne, Victoria, 3000

What is the Amplia Therapeutics Limited website address?

The website address for Amplia Therapeutics Limited is www.ampliatx.com

gfp927z

gfp927z 1分前

>>> Gaven Industries — Company Overview and Stock Information

Gaven Industries Inc. is a privately held U.S. manufacturer specializing in electromagnetic (RF, EMI, EMP, HEMP) shielding solutions, serving defense, industrial, critical infrastructure, and healthcare sectors. It is not p

Forensics888

Forensics888 2分前

What? Just calling out BS when someone repeatedly attacks me. See how easy that is? No knowledge required for that simple truth.

Homebrew

Homebrew 3分前

Says every garbage ticker....but never happens.
...short squeeze coming...

Smartypants2

Smartypants2 4分前

In other words, you don't have an innocent explanation why someone would do that 3 times within 13 seconds.

Zardiw

$SUNE - #DDAmanda Chart. Where does this go from here?

https://DDAmanda.com/Charts/DDAmandaSUNE.jpg

https://DDAmanda.com

Z

Zardiw

$SUNE - #DDAmanda Chart. Where does this go from here?

https://DDAmanda.com/Charts/DDAmandaSUNE.jpg

https://DDAmanda.com

Z

Zardiw

$SUNE - #DDAmanda Chart. Where does this go from here?

https://DDAmanda.com/Charts/DDAmandaSUNE.jpg

https://DDAmanda.com

Z

GenerationPoverty

GenerationPoverty 9分前

I was shocked to see it “gain” after that last PR, but I won’t complain about the price not falling on a Monday!

Dabeav

Dabeav 11分前

Nobody gives 2 shits bout degrees with this stock! Come on man!

US Market News

US Market News 12分前

IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded WarrantsJune 8, 2026 10:22 PM
PR Newswire (US) class="legendSpanClass"SOUTH SAN FRANCISCO, Calif., class="legendSpanClass"June 8, 2026 /PRNewswire/ -- IDEAY

biosectinvestor

biosectinvestor 12分前

Awesome find StonkMaster!

NWBO is listed as a collaborator in the newly posted Phase 2 Kalinski Alpha-DC1 ovarian-cancer trial.

The study is small but meaningful: an estimated 28-patient, open-label, non-randomized trial in advanced-stage ovarian, tubal, or peritoneal c

Dabeav

Dabeav 13分前

Nothing to say it’s not

Stumblebum

Stumblebum 16分前

Mine doesn’t include any Novartis involvement…..this EF one I feel is with a “partnership”…..I’ve for the last year or so always saw Novartis as the number one pharmaceutical that would buyout Uncy….whatever makes the sp go up I’m fine with it….got a whole mess of a lot of shares ….let the games beg

Kool Aid Man

Kool Aid Man 20分前

Baloney..."Vakser resigns" from all his tickers..but always returns! He does this every time he runs a ticker into the ground.

(2013) "ProTek Capital $PRPM announces today the resignation of Edward Vakser as chief executive officer of ProTek Capital..."
https://finance.yahoo.

along4zride

along4zride 23分前

Investors turn on each other as path forward narrows. Seasoned board veteran has pointed out the issues for years unfortunately going on deaf ears blinded by (FNMA) greed . While 47 relaxes watching ball game before opening bell daily optimistic investors are sweating bullets to see how much penny s

simplysouthern

simplysouthern 24分前

Why all the sudden volume? Is this being pumped by another site? Somedays there’s nothing then other days, it’s steady. Thoughts?

Koog

I'm an engineer with 35 years of experience in the semiconductor industry
You seem to be new here. That will automatically make anything you post here incorrect.

peafunke

peafunke 26分前

KCCO7913

KCCO7913 26分前

The SAM figure is likely derived mostly from LightCounting's reports. A couple years ago, a LightCounting report separated out PIC sales by material type and "TFLN and other" had its own category. I don't recall exactly off the top of my head, but I think it was estimated to be around $1.5 billion i

gmac8625

gmac8625 27分前

All good, natural questions. It would seemingly be the biggest blunder ever if they don’t do anything we have full capitulation right now and the stars seem to be aligned (or very close to). It is harder to come up with an excuse not to right now….my fear is the admin trying to be so cute to maximi

peafunke

peafunke 27分前

Let’s go. Next two weeks it is. But should see what’s behind door number one end of week 🤞🤞🤞

I leave for a bit and…. ;)

raiderz

raiderz 32分前

HIRU was so blatant with their promotion they earned a warning badge from OTC in fall of 2024.

After that, a set of paid accounts rotated in and out pumping HIRU here, on X, and stocktwts.

Where’s the goldenpump? Gone from here, and x. For someone who likes “cheapies”

DJurg

They sold 10.9M shares last quarter - and 4.1 M SO FAR this quarter - so they are by no means done selling shares

Duke Knockem

Duke Knockem 33分前

CHME is not current yet, but I'm expecting to see the fillings appearing really soon. next step should be the shell badge appearance on the OTC market website. I'm not too sure what is Belisarian strategy there ...they have encc and Zhud current and soon chme and AHFI ....yet they struggle to find a

Amplia Therapeutics

Vontobel Financial Produ...

Goldshore Resources

Short DAX X4 Kursindex

Flugger group AS

Vontobel Financial Produ...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。